Epicardial Application of Hydrogel with Amiodarone for Prevention of Postoperative Atrial Fibrillation in Patients After Coronary Artery Bypass Grafting.
O L BockeriaT N KanametovVladimir A ShvartzM A SokolskayaD Sh ZhuginisovM K SanakoevL A BockeriaPublished in: Journal of cardiovascular translational research (2019)
The objective of this study was to assess the safety and efficacy of local epicardial application of amiodarone-releasing hydrogel for prevention of postoperative atrial fibrillation (POAF) in patients after coronary artery bypass grafting. Patients were randomized into two groups: with the application of amiodarone-releasing hydrogel and the control group. It included 60 patients (47 males, 13 females) (mean age of 62 ± 8.5). POAF incidence differences were statistically significant between two groups: in the study group, the POAF incidence was 3.3%, while in the control group, the POAF incidence was 37% (p < 0.001). Statistically significant differences were revealed in the PQ interval duration. The risk of POAF incidence was calculated using the Cox regression model: the age and the application of amiodarone-releasing hydrogel application were statistically significant. Hospital length of stay in two groups was also different (р < 0.001). The age and the application of amiodarone-releasing hydrogel were statistically significant for POAF incidence.
Keyphrases
- end stage renal disease
- coronary artery bypass grafting
- ejection fraction
- atrial fibrillation
- newly diagnosed
- chronic kidney disease
- drug delivery
- risk factors
- percutaneous coronary intervention
- coronary artery disease
- peritoneal dialysis
- healthcare
- randomized controlled trial
- clinical trial
- patients undergoing
- left ventricular
- venous thromboembolism
- left atrial appendage
- open label
- single cell
- mitral valve
- wound healing
- study protocol
- double blind
- placebo controlled
- direct oral anticoagulants